Quarterly report · Q2
9987.TEDINET S100S6ZT
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.14T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥16.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥14.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥18.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥23.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥16.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥10.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.32T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.19T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥889.5bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥427.9bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥429.1bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥202.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥223.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥155.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥86.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥28.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥8.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥37.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥191.98 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.56 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.36 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥519m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥127.0bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥112.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥510m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.15T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥157.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥16.5bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥48.4bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥48.4bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥956m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥23.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥101.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥87.1bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥578m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.09T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.07T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥25.1bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥129.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥14.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 492
| Item | Context | Value | Unit |
|---|---|---|---|
| Work in process | CurrentQuarterInstant | 1989000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 4506000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 4367000000 | JPY |
| Other ca | Prior1YearInstant | 26279000000 | JPY |
| Other ca | CurrentQuarterInstant | 31084000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -1211000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -1173000000 | JPY |
| Current assets | Prior1YearInstant | 878169000000 | JPY |
| Current assets | CurrentQuarterInstant | 1046024000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 124827000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 124556000000 | JPY |
| Goodwill | Prior1YearInstant | 965000000 | JPY |
| Goodwill | CurrentQuarterInstant | 873000000 | JPY |
| Other ia | Prior1YearInstant | 9999000000 | JPY |
| Other ia | CurrentQuarterInstant | 11433000000 | JPY |
| Intangible assets | Prior1YearInstant | 10965000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 12307000000 | JPY |
| Investment securities | Prior1YearInstant | 93602000000 | JPY |
| Investment securities | CurrentQuarterInstant | 95806000000 | JPY |
| Other ioa | Prior1YearInstant | 39398000000 | JPY |
| Other ioa | CurrentQuarterInstant | 39578000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -865000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -851000000 | JPY |
| Investments and other assets | Prior1YearInstant | 132135000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 134533000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 267927000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 271396000000 | JPY |
| Assets | Prior1YearInstant | 1146097000000 | JPY |
| Assets | CurrentQuarterInstant | 1317420000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 666515000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 808293000000 | JPY |
| Income taxes payable | Prior1YearInstant | 6971000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 7402000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 8610000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 7592000000 | JPY |
| Provision for loss on anti monopoly act cl | Prior1YearInstant | 9790000000 | JPY |
| Provision for loss on anti monopoly act cl | CurrentQuarterInstant | 9790000000 | JPY |
| Other cl | Prior1YearInstant | 19388000000 | JPY |
| Other cl | CurrentQuarterInstant | 31703000000 | JPY |
| Current liabilities | Prior1YearInstant | 711274000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 864781000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 2323000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 2312000000 | JPY |
| Other ncl | Prior1YearInstant | 20973000000 | JPY |
| Other ncl | CurrentQuarterInstant | 22401000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 23297000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 24713000000 | JPY |
| Liabilities | Prior1YearInstant | 734571000000 | JPY |
| Liabilities | CurrentQuarterInstant | 889494000000 | JPY |
| Capital stock | Prior1YearInstant | 13546000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |